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PET-CT Principles and 
Applications in Lung Cancer 
Management
Long Chen, Hua Sun and Yunchao Huang
Abstract
Lung cancer is the most common malignant cancer throughout the world; the 
positron emission tomography/computed tomography (PET-CT) combines both the 
metabolism information from PET and anatomy details from CT, which is the state 
of the art. This manuscript introduced the PET-CT and applications in lung cancer 
diagnosing, staging, and treatment. Several aspects including clinical features, 
classification, grading and pathology of the lung cancer, principles of PET-CT, and 
evaluation of diagnosing and treatment had been covered. Detailed demonstra-
tion of each cancer subtype, staging criteria, and classification was described. The 
content will benefit the clinical doctors as well as radiologists.
Keywords: lung cancer, PET-CT
1. Lung cancer: an overview
1.1 Clinical features
Totally lung cancer remains the first leading cause of cancer incidence and 
mortality, with about 2.1 million incidence and 1.8 million deaths in 2018 among 
185 countries [1]. In 2018, an estimated 234,030 new cases of lung and bronchial 
cancer will be diagnosed, and 154,050 deaths are estimated to occur because of the 
disease [2]. The 5-year over survival rate is <20% once diagnosed [3]. Lung cancer 
is a unique disease for its etiologic agent is an addictive product cigarette, made and 
produced by an industry. Voluntary or involuntary (secondhand) cigarette smoking 
leads to nearly 90% cases, suggesting that effective public health policies to prevent 
initiation of smoking, oversight of tobacco products, and other tobacco control 
measures will play crucial roles in reducing lung cancer mortality [4]. Increased 
exposure to smoke from the burning of charcoal for heating and cooking is believed 
to contribute to the high lung cancer incidence, rather than smoking that is thought 
to be the leading cause of high lung cancer incidence in western countries [5].
1.2 Classification
1.2.1 Non-small cell lung cancer (NSCLC)
There are four major cell types of lung cancer according to the World Health 
Organization (WHO) classification: adenocarcinoma (ADC), squamous cell 
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carcinoma (SCC), large cell carcinoma, and small cell carcinoma [6]. The first three 
types are also called non-small cell lung cancer, consisting of the most majority of 
all lung cancers. This molecular-based classification is important for therapeutic 
decision-making for several reasons: (i) overall survival was statistically superior 
for cisplatin/pemetrexed versus cisplatin/gemcitabine in patients with ADC 
(12.6 versus 10.9 months, respectively). In contrast, in SCC patients, there was a 
significant improvement in survival with cisplatin/gemcitabine versus cisplatin/
pemetrexed (10.8 versus 9.4 months, respectively) [7]. (ii) SCC patients receiving 
treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) are prone 
to suffering from life-threatening major hemoptysis [8]. (iii) ADC patients are 
likely to harbor epidermal growth factor receptor (EGFR) mutations which are 
predictive of responsiveness to tyrosine kinase inhibitors (TKI).
Age, smoking history, previous cancer history, family history, occupational 
exposures, other lung diseases (chronic obstructive pulmonary disease [COPD], 
pulmonary fibrosis), exposure to infectious agents (e.g., endemic areas of fungal 
infections, tuberculosis) or risk factors, or history suggestive of infection are all 
potential or obvious risk factors.
1.2.2 Small cell lung cancer
Neuroendocrine tumors account for about 20% of lung cancers, and most are small 
cell lung cancer (SCLC) [9]. SCLC is sometimes called oat cell cancer, accounting for 
approximately 10–15% of lung cancers, and is considered as a separate entity from 
NSCLC due to its early metastases and relative response to chemotherapy and radia-
tion. Unfortunately, although small cell lung cancer usually responds very well initially 
to treatment, long-term survival remains low. To be specific, the 5-year survival rate 
is 31% for stage I, 19% for stage II, 8% for stage IV, and only 2% for stage IV disease. 
There is no significant difference in the AJCC TNM staging system between NSCLC 
and SCLC. In fact, in addition to the TNM staging, SCLC can also be defined as “lim-
ited stage” when the tumor is encompassed within a tolerable radiation field or defined 
as “extensive stage” when the tumor is too large or too widespread to be encompassed 
within tolerable radiation field, according to the older Veterans Administration (VA) 
[10]. Then the NCCN Panel adopted a combined approach for staging SCLC using 
both the AJCC TNM staging system and the VA scheme for SCLC. In applying the 
TNM classifications to the VA system, the so-called limited-stage SCLC is defined 
as stage I to III (any T, any N, M0) which can be effectively treated with definitive 
radiation therapy, while extensive-stage SCLC is defined as stage IV (any T, any N, 
M1a/b) or T3-T4 harboring multiple lung nodules or having tumor volume that is too 
large to be encompassed in a tolerable radiation plan. Positron emission tomography-
computed tomography (PET-CT) scan will be useful to assess for distant metastases 
when limited-stage disease is suspected, and a bone scan can be performed if PET-CT 
is ambiguous or not available; bone biopsy can be applied if the bone scan is equivocal. 
Although PET-CT is superior to PET or CT alone in detecting most metastatic sites, it is 
inferior to MR for the detection of brain metastases [11].
1.2.3 Rare carcinoma of the lung
Adenosquamous carcinoma (ASC) is a rare subtype of lung cancer, making 
up 0.4–4% of all lung cancer cases, and it is made up of two of the main tumor 
types: adenocarcinoma and squamous [12]. People suffering from ASC are prone 
to survive within a shorter time than those with pure lung adenocarcinomas or 
squamous cell carcinomas of the lung, no matter whether it is diagnosed earlier or 
later. In addition, the proportion of the adenocarcinoma/squamous cell component 
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has no effect on the outcome. Cisplatin (a chemotherapy drug used in the squamous 
cancer cell) rather than the pemetrexed (commonly used in adenocarcinomas) 
tends to be more effective in the treatment of ASC. Some studies have shown that 
ASC has its own clinical characteristics: patients are mainly males, the average age 
is 68.7 years old, most patients with ASC have smoking history, and most of the 
diseases are located in the peripheral rather than the central segment [12].
Carcinoid tumors are a type of tumor that relates to the neuroendocrine sys-
tem, accounting for about 1–6% of all lung tumors, and approximately a quarter 
of patients suffering from carcinoid have no symptoms at the time of discovery. 
Although a common X-ray or chest CT scan can detect this disease, 18F-FDG PET-CT 
scans are not sensitive enough to discover it or see if they have spread distantly 
because no obvious uptake can be discovered. Consequently, octreotide rather than 
FDG will be given if some are suspected of having a carcinoid tumor [13].
Granular cell lung tumors are extremely rare, accounting for approximately 
0.2% of all lung tumors. Narrowed airways, which are caused by small, firm, and 
solitary nodules, can always be found. However, in most situations, this kind of 
disease is benign. Malignant or cancerous granular cell lung is even rarer [14].
Sarcomatoid carcinomas are another rare lung carcinoma, making up 0.3–3% of 
all NSCLC. Some studies have shown that heavy smoking and exposure to asbestos 
possibly, at least partially, are responsible for this disease [15].
1.3 Molecular pathology of lung cancer
Traditionally, according to histological features, NSCLC has been classified into 
small cell and non-small cell lung cancers and further was subdivided into squamous 
cell carcinoma, adenocarcinoma, and large cell carcinoma. Historically, little attention 
was given to the differentiation of the specific subtypes because there are no thera-
peutic implications, especially prior to the 2004 WHO classification. Various driver 
mutations have been associated with these cancers over time [16]; the genetic altera-
tions and specific protein expression level have attracted much attention (Figure 1).
Figure 1. 
Classifications of lung cancer: from histology to molecular based [16] (Reprinted with permission. © 2013 by 
the American Society of Clinical Oncology. All rights reserved).
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1.4 TNM staging
The primary tumor (T), regional lymph node involvement (N), and dis-
tant metastasis (M) are the bases of staging for lung cancer. The International 
Association Society of Lung Cancer (IASLC) recommends the TNM classification 
of malignant tumors published by the Union Internationale Contre Le Cancer 
(UICC) and the American Joint Committee on Cancer (AJCC), and the latest eighth 
edition was published in 2016 [17]. Based on the different T, N, and M combina-
tions, patients are grouped into different stages, which will determine the clinical 
treatments and can also predict various prognoses. The staging system is described 
in Table 1, and the stage groupings based on the TNM are listed in Table 2.
T—Primary tumor
T category T criteria
Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in 
sputum or bronchial washings but not visualized by imaging or bronchoscopy
T0 No evidence of primary tumor
Tis Carcinoma in situ
Squamous cell carcinoma in situ (SCIS)
Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, ≤3 cm in greatest 
dimension
T1 Tumor ≤3 cm in greatest dimension, surrounded by lung or visceral pleura, without 
bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the 
main bronchus)
T1mi Minimally invasive adenocarcinoma: adenocarcinoma (≤3 cm in greatest dimension) with a 
predominantly lepidic pattern and ≤ 5 mm invasion in greatest dimension
T1a Tumor ≤1 cm in greatest dimension. A superficial, spreading tumor of any size whose 
invasive component is limited to the bronchial wall and may extend proximal to the main 
bronchus; also is classified as T1a, but these tumors are uncommon
T1b Tumor >1 cm but ≤2 cm in greatest dimension
T1c Tumor >2 cm but ≤3 cm in greatest dimension
T2 Tumor >3 cm but ≤5 cm or having any of the following features:
• Involves the main bronchus regardless of distance to the carina, but without involve-
ment of the carina
• Invades visceral pleura (PL1 or PL2)
• Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, 
involving part or all of the lung
T2 tumors with these features are classified as T2a if ≤4 cm or if the size cannot be determined 
and T2b if >4 cm but ≤5 cm in greatest dimension
T2a Tumor >3 cm but ≤4 cm in greatest dimension
T2b Tumor >4 cm but ≤5 cm in greatest dimension
T3 Tumor >5 cm but ≤7 cm in greatest dimension or directly invading any of the following: 
parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal 
pericardium; or separate tumor nodule (s) in the same lobe as the primary
T4 Tumor >7 cm or tumor of any size invading one or more of the following: the diaphragm, 
mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, 
or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary
N—Regional lymph
N category N criteria
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1.5 Synoptic reporting of lung cancer
Synoptic reporting for lung cancer aimed to standardize diagnostic reports, 
including recommended clinical and histopathologic variables. This includes the 
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, 
or supraclavicular lymph node(s)
M 
category
M criteria
M0 No distant metastasis
M1 Distant metastasis
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules 
or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with 
lung cancer are a result of the tumor. In a few patients, however, multiple microscopic 
examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody 
and not an exudate. If these elements and clinical judgment dictate that the effusion is not 
related to the tumor, the effusion should be excluded as a staging descriptor
M1b Single extrathoracic metastasis in a single organ (including involvement of a single 
nonregional node)
M1c Multiple extrathoracic metastases in a single organ or in multiple organs
Table 1. 
The eighth edition of TNM for lung cancer.
Stage group T N M
Stage IA T1 N0 M0
Stage IA1 T1mi, T1a N0 M0
Stage IA2 T1b N0 M0
Stage IA3 T1c N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
Stage IIB T1a-c, T2a, b N1 M0
T3 N0 M0
Stage IIIA T1a-c, T2a, b N2 M0
T3 N1 M0
T4 N0, N1 M0
Stage IIIB T1a-c, T2a, b N3 M0
T3, T4 N2 M0
Stage IIIC T3, T4 N3 M0
Stage IVA Any T Any N M1a, b
Stage IVB Any T Any N M1c
Table 2. 
Stage groupings in the eighth edition of TNM staging system for lung cancer.
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Terms
Clinical details
Clinical information provided on request
Nature of the resection
Additional extrapulmonary tissue
Site and laterality of tumor
Results of previous cytological investigations or biopsies
Details of any previous treatment of the current tumor
Details of previous cancer diagnosis
Risk factors for lung cancer (e.g., smoking history, ethnicity, and asbestos exposure)
Clinical tumor stage
New primary cancer or recurrence
Pathology accession number
Principal clinician caring for the patient
Other clinical information received
Macroscopic
Operative procedure
Specimen laterality
Attached anatomical structures
Accompanying specimens
Block identification key
Tumor site
Tumor location
Separate tumor nodules
 Number of tumors
 Site
Maximum tumor dimension
Macroscopic appearance of pleura overlying tumor
Extent of direct spread of tumor to other tissues
Distance of tumor to closest resection margin
Tumor involves main bronchus within 20 mm of carina
Lymph nodes
 Site(s) and number of lymph nodes
Atelectasis/obstructive pneumonitis
 Extent
Nonneoplastic lung
Other relevant information and comments
Microscopic
Histological tumor type
 Adenocarcinoma classification
Histological grade
Visceral pleural invasion
 Extent of pleural involvement
Lymphovascular invasion
 Vessel(s) involved
 Type of involvement
Perineural invasion
Pathological staging (AJCC seventh edition)
 Suffixes
 Primary tumor (T)
 Regional lymph nodes (N)
 Distant metastasis (M)
Residual tumor status
Completeness of surgical resection
Diagnostic summary
Table 3. 
Synoptic reporting of lung cancer.
7PET-CT Principles and Applications in Lung Cancer Management
DOI: http://dx.doi.org/10.5772/intechopen.88717
clinical details and macroscopic, microscopic, and pathological staging as essential 
requirements. In addition, there should be an assessment of lymphovascular inva-
sion and neurotropism and the presence of absence of satellite lesions; all these are 
shown in Table 3.
2. Management of lung cancer
2.1 Surgical management of primary lung cancer
Generally speaking, surgery is the best chance for stage I or II lung cancer 
patients [18]. Surgical oncology consultation is necessary for any patient being 
considered for local therapy. The general treatment plan, the essential imaging 
studies, and laboratory results should be determined before any nonemergency 
treatment is started. If patients cannot tolerate surgery or are inoperable, mini-
mally invasive techniques, such as sublobar resection, can be a better choice [19]. 
Selected patients, including those who are not eligible for lobectomy and those with 
a peripheral nodule 2 cm or less with very low-risk features, are recommended to go 
through sublobar resection, either segmentectomy (preferred) or wedge resection. 
On the other hand, segmentectomy (preferred) or wedge resection should achieve 
parenchymal resection margins that are (1) 2 cm or more or (2) the size of the 
nodule or more.
2.2 Radiotherapy
The principles of radiation therapy in the NSCLC algorithm has been described 
thoroughly, including the following: general principles for early-stage, locally 
advanced, and advanced NSCLC; target volumes, prescription doses, and normal 
tissue dose constraints for early-stage, locally advanced, and advanced NSCLC; 
and RT simulation, planning, and delivery [20]. Treatment recommendations 
should be made by a multidisciplinary team. Because of the potential role of radio-
therapy in all stages of NSCLC, whether it is a definitive treatment or palliative 
treatment is not known. Radiotherapy uses for NSCLC include, but are not limited 
to, (1) definitive treatment of locally advanced NSCLC, usually combined with 
chemotherapy; (2) definitive treatment of early NSCLC in patients with surgical 
contraindications; (3) partial preoperative or postoperative treatment of surgical 
patients; (4) treatment of limited recurrence and metastasis; and/or (5) palliative 
treatment of incurable NSCLC patients [21–23].
2.3 Immunotherapy and targeted therapy
Specific targeted therapies can be used to treat advanced NSCLC. Bevacizumab 
is a monoclonal antibody, targeting vascular endothelial growth factor, while 
ramucirumab is a recombinant monoclonal antibody that targets VEGF receptors. 
Cetuximab is a monoclonal antibody that targets EGFR. Erlotinib, gefitinib, and afa-
tinib inhibit EGFR-sensitizing mutations; osimertinib inhibits both EGFR-sensitizing 
mutations and T790 M. ALK rearrangement, ROS1 rearrangement, and MET were all 
inhibited by crizotinib. Patients with ALK rearrangement are recommended to ceri-
tinib which inhibits the IGF-1 receptor. Alectinib inhibits ALK and RET rearrange-
ment. Brigatinib inhibits various ALK rearrangements and other targets. Dabrafenib/
trametinib inhibits the BRAF V600E mutation; trametinib also inhibits MEK; both 
drugs inhibit different kinases in the RAS/RAF/MEK/ERK pathway [24, 25].
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3. Role of PET-CT in lung cancer
3.1 Principles of PET-CT
PET-CT is a nuclear medicine technique that combines a positron emission 
tomography (PET) scanner with an X-ray computed tomography (CT) scanner. 
The anatomical imaging obtained by CT scan and the functional imaging obtained 
by PET (which depicts the spatial distribution of metabolic or biochemical activity 
in vivo) can achieve the same machine fusion more accurately, and the generated 
fusion image can be based on general software and control system to obtain 2D and 
3D image reconstruction. Previously pure PET imaging cannot provide accurate 
anatomical positioning, and thus its value was limited, while PET-CT revolution-
ized medical diagnosis in many areas by increasing the accuracy of anatomical 
positioning in functional imaging. For example, the diagnosis and classification of 
benign and malignant tumors, the development of surgical plans, and the delin-
eation of radiotherapy target areas have rapidly changed under the influence of 
PET-CT availability [26]. PET-CT-based grading staging has significantly changed 
clinical decisions; so many hospitals’ nuclear medicine departments have gradually 
reduced the usage of traditional PET devices and replaced them with PET-CT. One 
of the barriers to the wider use of PET-CT is its relatively expensive price. Another 
obstacle is the difficulty and cost of producing and transporting of radiopharma-
ceuticals for PET imaging, which usually have a short half-life (e.g., radioactive 
fluorine-18). The half-life of (18F) is used to track glucose metabolism (using 
fluorodeoxyglucose (FDG)) for only 106 minutes, and its production requires very 
expensive cyclotrons and radiopharmaceutical production lines [27].
3.2 Preoperative staging
Identifying the stage of lung cancer not only helps determine the appropriate 
treatment but also is essential for prognosis. Incorrect staging of lung cancer can 
lead to mistaken resections of benign nodules and early local or distant relapse 
after surgery with curative intent. Barbara randomly assigned patients referred 
for preoperative staging of NSCLC to either conventional staging plus PET-CT or 
conventional staging alone followed until death or for at least 12 months. They 
defined ineffective thoracotomy as any of the following: thoracotomy, pathologi-
cally confirmed mediastinal lymph node involvement (stage IIIA [N2]), stage 
IIIB or IV disease, or benign lung disease; exploratory thoracic incision; or tho-
racotomy in patients who have relapsed or died for any reason within 1 year after 
randomization. Ninety-eight patients were assigned to the PET-CT group and 91 
to the conventional staging group. Sixty patients in the PET-CT group and 73 in 
the conventional staging group underwent thoracotomy (P = 0.004). Among these 
thoracotomies, 21 in the PET-CT group and 38 in the conventional staging group 
were futile (P = 0.05). Both groups had a reasonable thoracotomy and had similar 
survival. The use of PET-CT in the preoperative staging of NSCLC reduced the total 
number of thoracotomy and the number of ineffective thoracotomy, but did not 
affect overall mortality [28] (Figure 2).
3.3 Evaluation of treatment effect
Franco et al. conducted research aiming to evaluate the utility between PET-CT 
and the contrast-enhanced (CE) CT. The low-dose CT scans were performed for 
attenuation correction of the PET images, and the PET scanner was fully cross-
calibrated, allowing accurate standard uptake value measurements. The protocols 
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for CE-CT are the following: (1) all chest CT scans were performed according to 
the conventional low-dose chest multi-detection CT protocol, including head-
to-tail orientation, arms raised on the head, single breath, and the amount of 
scan from the diaphragm level to the level directly above the chest entrance; and 
(2) the injected volume of contrast medium was tailored to the individual body 
weight: 60 mL at 2 mL/s for <50 kg or 80 mL at 2.5 mL/s at 50 kg or heavier with 
a fixed contrast delay of 35 seconds. The study enrolled 96 patients who received 
curative-intent treatment, and the results showed that the sensitivity, specificity, 
and positive predictive value for detecting cancer recurrence (95% confidence 
interval) were 0.88, 0.62, and 0.56 for PET-CT and 0.93, 0.72, and 0.64 for 
CE-CT, respectively, indicating that PET-CT is not superior to CE-CT in detecting 
cancer recurrence during 2 years after curative-intent treatment of non-small cell 
lung cancer [29].
3.4 Surveillance
Using systematic review and meta-analysis, Nie et al. evaluated the prognostic 
value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) for small 
cell lung cancer and used the pooled hazard ratio (HR) to measure the influence of 
MTV and TLG on survival. They found that patients with high MTV are associated 
with a significantly poorer prognosis OS and PFS, while high TLG is associated with 
a significantly poorer prognosis regarding OS for SCLC [30].
3.5 Guiding biopsy
When lung cancer is discovered, accurate staging at baseline is necessary to 
maximize patient benefit and cost-effective use of healthcare resources. Although 
CT remains a powerful tool for the staging of lung cancer, advances in combined 
imaging modalities, specifically PET-CT, have improved the baseline staging 
accuracy over that of CT alone [31]. FDG PET-CT has been considered a “meta-
bolic biopsy” tool in the evaluation of nonlung lesions with indeterminate biopsy 
results [32]. PET-CT data coregistered with intraprocedural CT images could guide 
needle placement in the viable portion of the lesion and thus increase the chances 
of achieving a definitive diagnosis and CT-guided, fine-needle aspiration (FNA) 
biopsies performed with FDG PET scans of pulmonary lesions contributing sub-
stantially to the management and treatment of pulmonary disease [33].
Figure 2. 
Preoperative staging of NSCLC between PET-CT group and conventional staging group.
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Figure 3. 
Axial PET, CT, PET-CT, and MIP images in a patient of adenocarcinoma. An irregular mass showing higher 
FDG uptake in the lesion was discovered in the anterior segment of the right upper lobar.
4. PET-CT in lung cancer: teaching cases
4.1 Adenocarcinoma
Teaching point: adenocarcinoma mainly located in the peripheral segment and 
shows higher FDG uptake (Figure 3).
4.2 SCC
Teaching point: adenocarcinoma is mainly located in the central segment and 
shows moderate FDG uptake (Figure 4).
4.3 Large cell lung cancer
Teaching point: large cell lung cancer always shows moderate FDG uptake and 
diffused distribution (Figure 5).
4.4 Small cell lung cancer
Teaching point: small cell lung cancer shows a small mass with moderate FDG 
uptake (Figure 6).
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Figure 4. 
Axial PET, CT, PET-CT, and MIP images in a patient of squamous cell carcinoma. An irregular mass showing 
moderate FDG uptake in the lesion was discovered in the central segment of the right lung, with inflammation 
around the malignant lung lesion.
Figure 5. 
Axial PET, CT, PET-CT, and MIP images in a patient of large cell cancer. Multisite masses showing higher 
FDG uptake in the lesion were discovered in the left and right lung field, with inflammation and enlarged 
lymph node in the mediastinum.
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5. Conclusions
The current chapter focused on the PET-CT utility in lung cancer diagnosis and 
summarized the basic clinic utilities, including guiding to select the biopsy site, 
improving target delineation accuracy, evaluating disease progression on first-line 
therapy, and detecting hilar, mediastinal nodes and metastatic disease. PET-CT 
scans have been widely used to help evaluate the extent of disease and to provide 
more accurate staging and has been recommended by the NCCN. Patients with sus-
pected malignant lung nodules should be scanned by PET-CT for accurate diagnosis 
of local or distant metastasis.
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